论文部分内容阅读
目的:观察依达拉奉联合舒血宁治疗急性脑梗死的疗效及安全性。方法:采用随机、双盲对照,选择发病48h内的脑梗死患者85例,随机分为依达拉奉联合舒血宁(联合组)组和舒血宁(对照组)组。联合组予依达拉奉注射液30mg加0.9%氯化钠250mL静脉滴注,bid,同时给予舒血宁20mL加5%葡萄糖500mL静脉滴注,qd,连续14d;对照组给予舒血宁20mL加5%葡萄糖500mL静脉滴注,qd,连续14d。2组均口服肠溶阿司匹林100mg,qd。治疗前及治疗2周后进行临床疗效比较及神经功能缺损评分比较。结果:联合组与对照组相比,联合组总有效率为93.02%,明显好于对照组(80.95%)(P<0.01);联合组神经功能缺损评分与对照组比较明显降低(P<0.01);未见明显不良反应。结论:依达拉奉联合舒血宁治疗急性脑梗死安全、有效。
Objective: To observe the efficacy and safety of edaravone and shuxuening in the treatment of acute cerebral infarction. Methods: A total of 85 patients with cerebral infarction within 48 hours of onset were randomly divided into two groups: edaravone combined with Shuxuening (combination group) and Shuxuening (control group). Combination group to edaravone injection 30mg plus 0.9% sodium chloride 250mL intravenous infusion, bid, given Shuxuening 20mL plus 5% glucose 500mL intravenous infusion, qd, continuous 14d; control group Shushuoning 20mL Add 5% glucose 500mL intravenous drip, qd, continuous 14d. 2 groups were oral enteric-coated aspirin 100mg, qd. Before treatment and after 2 weeks of treatment compared the clinical efficacy and neurological deficit score comparison. Results: Compared with the control group, the total effective rate in the combined group was 93.02%, which was significantly better than that in the control group (80.95%) (P <0.01); the neurological deficit score in the combined group was significantly lower than that in the control group (P <0.01) ); No obvious adverse reactions. Conclusion: Edaravone and Shuxuening are safe and effective in treating acute cerebral infarction.